Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 672.

https://doi.org/10.1182/blood-2025-672

Published: 2025

Journal Articles

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Shilin Gan, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2025-2377

Published: 2025

Journal Articles

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2368.

https://doi.org/10.1182/blood-2025-2368

Published: 2025

Journal Articles

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2025-3708

Published: 2025

Journal Articles

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Rui Liu, Danyang Li, Zhonghua Fu, Fan Yang, Miaomiao Cao, Lixia Ma, Yuelu Guo, Alex H. Zhang, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2025-3706

Published: 2025

Journal Articles

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Danyang Li, Biping Deng, Qinlong Zheng, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 7259.

https://doi.org/10.1182/blood-2025-7259

Published: 2025

Journal Articles

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2025-5484

Published: 2025

Journal Articles

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Miaomiao Cao, Hui Shi, Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5489.

https://doi.org/10.1182/blood-2025-5489

Published: 2025

Journal Articles

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2024-202415

Published: 2024

Journal Articles

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Lixia Ma, Rui Liu, Fan Yang, Yuelu Guo, Yimeng Dou, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2024-200523

Published: 2024

Journal Articles

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 3079.

https://doi.org/10.1182/blood-2024-202286

Published: 2024

Journal Articles

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Bian Wei, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Qinlong Zheng, Biping Deng, Zhonghua Fu, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 6549.

https://doi.org/10.1182/blood-2024-206676

Published: 2024

Journal Articles

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Biping Deng, Chen Chen, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 7247.

https://doi.org/10.1182/blood-2024-201274

Published: 2024

Journal Articles

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Na Zhang, Rui Liu, Fan Yang, Lixia Ma, Yuelu Guo, Zhonghua Fu, Haifeng Wu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2024) 144 (Supplement 1): 1745.

https://doi.org/10.1182/blood-2024-202403

Published: 2024

Journal Articles

Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma

Lixia Ma, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 3434.

https://doi.org/10.1182/blood-2023-184412

Published: 2023

Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 6922.

https://doi.org/10.1182/blood-2023-177836

Published: 2023

Journal Articles

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Shaomei Feng, Teng Xu, Haidi Liu, Peihao Zheng, Lixia Ma, Hui SHI, Tong Wu, Fan Yang, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2023-182797

Published: 2023

Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2022) 140 (Supplement 1): 7548–7549.

https://doi.org/10.1182/blood-2022-168018

Published: 2022

Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu

Blood (2022) 140 (Supplement 1): 10384–10385.

https://doi.org/10.1182/blood-2022-164446

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Utilizing BTK Inhibitors for Maintenance and Long-Term Control Following CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Impact of CD58 Mutations on CAR-T Cell Therapy in B-Cell Non-Hodgkin Lymphoma: Clinical Insights and Therapeutic Potential

Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL

The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma

Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only